© 2021 BioMarin. All rights reserved.
| Beta | 0.59 |
|---|---|
| Shares Outstanding | 182.7M |
| Average Volume (10 days) | 902.3K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
| Earnings (TTM) | $4.43 |
|---|---|
| Sales (TTM) | $7.44 |
| Book Value (MRQ) | $22.48 |
| Cash Flow (TTM) | $0.45 |
| Cash (MRQ) | $5.87 |
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 10 | |
|---|---|---|
| Buy | 0 | |
| Hold | 6 | |
| Underperform | 0 | |
| Sell | 0 |
Jeffrey R. Ajer EVP, Chief Commercial Officer | (1,652) Sell Mar 30, 2021 |
|---|---|
Jeffrey R. Ajer EVP, Chief Commercial Officer | (1,181) Sell Mar 24, 2021 |
Henry J. Fuchs President, Worldwide R&D | (2,454) Dispose Mar 22, 2021 |
Brian Mueller EVP, Chief Financial Officer | (516) Dispose Mar 22, 2021 |
Jeffrey R. Ajer EVP, Chief Commercial Officer | (1,513) Dispose Mar 22, 2021 |